Reassuring Data on Cancer Risk with Contemporary RA Drugs

A limitation of the study is that follow-up time and statistical power are “inherently limited to less than 10 years,” given the relatively recent introduction of non-TNF inhibitor therapy in RA.

Despite this, they say it can be concluded from this study that “short-to medium-term use of tocilizumab, abatacept, rituximab, or anti-TNF drugs seems to be safe with regard to risks of incident cancer.”

Reference

Wadström H, Frisell T, Askling J, et al. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med. 2017 Sept 18. [Epub ahead of print]

Patient histories, clinician reports of condition also called Köhlmeier-Degos disease underscore need for integrated, multidisciplinary care

Tumor necrosis factor alpha inhibition and the risk of solid malignancies

Reckless approach versus missed opportunity?

A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

Malignant Atrophic Papulosis Is Challenging to Diagnose, Treat

Are We Playing It Safe?

TNF Blockade for SLE

The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

Related Articles